Effects of dynamic change in fetuin-A levels from the first to the second trimester on insulin resistance and gestational diabetes mellitus: a nested case-control study

Chuyao Jin, Lizi Lin, Na Han, Zhiling Zhao, Zheng Liu, Shusheng Luo, Xiangrong Xu, Jue Liu, Haijun Wang, Chuyao Jin, Lizi Lin, Na Han, Zhiling Zhao, Zheng Liu, Shusheng Luo, Xiangrong Xu, Jue Liu, Haijun Wang

Abstract

Objective: To examine the effects of dynamic change in fetuin-A levels before the diagnosis of gestational diabetes mellitus (GDM) on insulin resistance and GDM.

Research design and methods: A total of 135 women with GDM and 135 normal glucose tolerance (NGT) women with matched age (±2 years old) and gestational age at taking the oral glucose tolerance test (OGTT) were included in this nested case-control study. Fasting venous blood samples were collected at the prenatal visit of the first trimester and during OGTT of the second trimester. Plasma concentration of fetuin-A and insulin was determined.

Results: The plasma fetuin-A concentration in women with GDM was significantly higher than NGT controls in both the first trimester (medians: 403.0 pg/mL vs 273.4 pg/mL; p<0.05) and the second trimester (medians: 475.7 pg/mL vs 290.8 pg/mL; p<0.05) and notably increased from the first to the second trimester. Multivariate linear regression analysis showed that the change in fetuin-A concentration was associated with the changes in fasting insulin, homeostasis model assessment (HOMA) of insulin resistance, and HOMA of β-cell function (HOMA-β) (p<0.05). The highest quartile of the increase in fetuin-A concentration from the first to the second trimester was associated with a higher risk of developing GDM compared with the lowest quartile (OR 2.14; 95% CI 1.05 to 4.37).

Conclusions: The dynamic change in fetuin-A levels was associated with the changes in insulin resistance and β-cell function from the first to the second trimester, and was associated with an increased risk of the development of GDM, indicating that fetuin-A could be a biomarker to predict the risk of GDM.

Trial registration number: NCT03814395.

Keywords: fetuin; gestational diabetes mellitus; insulin resistance.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Fetuin-A (A), fasting insulin (B), HOMA-IR (C), and HOMA-β (D) levels in the first and the second trimesters. Data were presented as medians (IQR). *P

Figure 2

Receiver operating characteristic (ROC) curves…

Figure 2

Receiver operating characteristic (ROC) curves to assess the accuracy of fetuin-A levels in…

Figure 2
Receiver operating characteristic (ROC) curves to assess the accuracy of fetuin-A levels in the first trimester to predict gestational diabetes mellitus (GDM).
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves to assess the accuracy of fetuin-A levels in the first trimester to predict gestational diabetes mellitus (GDM).

References

    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet Med 1998;15:539–53. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S
    1. International Diabetes Federation IDF diabetes atlas. 8th edn Brussels, Belgium, 2017.
    1. Gao C, Sun X, Lu L, et al. . Prevalence of gestational diabetes mellitus in mainland China: A systematic review and meta-analysis. J Diabetes Investig 2019;10:154–62. 10.1111/jdi.12854
    1. Johns EC, Denison FC, Norman JE, et al. . Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab 2018;29:743–54. 10.1016/j.tem.2018.09.004
    1. Trepanowski JF, Mey J, Varady KA. Fetuin-A: a novel link between obesity and related complications. Int J Obes 2015;39:734–41. 10.1038/ijo.2014.203
    1. Srinivas PR, Wagner AS, Reddy LV, et al. . Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445–55. 10.1210/mend.7.11.7906861
    1. Auberger P, Falquerho L, Contreres JO, et al. . Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58:631–40. 10.1016/0092-8674(89)90098-6
    1. Mathews ST, Singh GP, Ranalletta M, et al. . Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450–8. 10.2337/diabetes.51.8.2450
    1. Guo VY, Cao B, Cai C, et al. . Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 2018;55:87–98. 10.1007/s00592-017-1068-9
    1. Bellamy L, Casas J-P, Hingorani AD, et al. . Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773–9. 10.1016/S0140-6736(09)60731-5
    1. Farhan S, Handisurya A, Todoric J, et al. . Fetuin-A characteristics during and after pregnancy: result from a case control pilot study. Int J Endocrinol 2012;2012:1–5. 10.1155/2012/896736
    1. Iyidir OT, Degertekin CK, Yilmaz BA, et al. . Serum levels of fetuin a are increased in women with gestational diabetes mellitus. Arch Gynecol Obstet 2015;291:933–7. 10.1007/s00404-014-3490-3
    1. Kalabay L, Cseh K, Pajor A, et al. . Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol 2002;147:243–8. 10.1530/eje.0.1470243
    1. Kansu-Celik H, Ozgu-Erdinc AS, Kisa B, et al. . Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels. Arch Endocrinol Metab 2019;63:121–7. 10.20945/2359-3997000000126
    1. Kralisch S, Hoffmann A, Lössner U, et al. . Regulation of the novel adipokines/ hepatokines fetuin A and fetuin B in gestational diabetes mellitus. Metabolism 2017;68:88–94. 10.1016/j.metabol.2016.11.017
    1. Šimják P, Cinkajzlová A, Anderlová K, et al. . Changes in plasma concentrations and mRNA expression of hepatokines fetuin a, fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus. Physiol Res 2018;67:S531–42. 10.33549/physiolres.934017
    1. Craig CL, Marshall AL, Sjöström M, et al. . International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381–95. 10.1249/01.MSS.0000078924.61453.FB
    1. Ma Y-C, Zuo L, Chen J-H, Luo Q, et al. . Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937–44. 10.1681/ASN.2006040368
    1. Matthews DR, Hosker JP, Rudenski AS, et al. . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9. 10.1007/BF00280883
    1. Weinert LS. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: Comment to the International association of diabetes and pregnancy study groups consensus panel. Diabetes Care 2010;33:e97 author reply e98 10.2337/dc10-0544
    1. Pal D, Dasgupta S, Kundu R, et al. . Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012;18:1279–85. 10.1038/nm.2851
    1. Pinnaduwage L, Ye C, Hanley AJ, et al. . Changes over time in hepatic markers predict changes in insulin sensitivity, β-cell function, and glycemia. J Clin Endocrinol Metab 2018;103:2651–9. 10.1210/jc.2018-00306
    1. Malin SK, del Rincon JP, Huang H, et al. . Exercise-Induced lowering of fetuin-A may increase hepatic insulin sensitivity. Med Sci Sports Exerc 2014;46:2085–90. 10.1249/MSS.0000000000000338
    1. Mørkrid K, Jenum AK, Sletner L, et al. . Failure to increase insulin secretory capacity during pregnancy-induced insulin resistance is associated with ethnicity and gestational diabetes. Eur J Endocrinol 2012;167:579–88. 10.1530/EJE-12-0452

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren